What normally happens across an HSCT

In an allogeneic HSCT, healthy blood-forming stem cells from a donor replace or restore a recipient's marrow after conditioning treatment reduces the recipient's own marrow and, in most cases, immune function. Conditioning regimens are not all the same intensity: myeloablative regimens are dosed to eliminate the recipient's marrow function, so recovery depends on the graft, while reduced-intensity and non-myeloablative regimens suppress but do not fully ablate marrow and immune function, which changes the expected depth and duration of the cytopenic nadir and how quickly donor chimerism is expected to predominate. The transplant program's regimen selection, not a fixed universal rule, determines which pattern applies to a given case. In an autologous HSCT, the recipient's own stem cells are collected in advance and returned after conditioning, so donor and recipient are the same person. Graft sources include marrow, mobilized peripheral blood, and umbilical cord blood, and the source affects collection method, cell content, and expected recovery timing.

Before any cells are collected, the laboratory supports donor and recipient identification and testing that will follow the graft through collection, processing, release, and administration. This includes tissue typing, infectious-disease screening, blood group and antibody testing, and baseline organ-function and blood-count studies that give later results something to be compared against. None of this testing by itself authorizes a transplant; it produces the evidence that the transplant team weighs in a distinct clinical decision.

Once a product is collected, the laboratory measures what is in it: how many cells, what fraction are viable, how many carry the CD34 marker used to estimate the transplantable progenitor-cell dose, whether the product is sterile, and how it is labeled and tracked. After infusion, conditioning-related cytopenias are expected, and the laboratory watches blood counts recover while collecting the recurring specimens that establish engraftment. Further out, the laboratory reports chimerism, the mix of donor and recipient genetic signal in blood or marrow, and disease-specific MRD testing when a diagnosis was being monitored before transplant.

Anything that breaks this normal sequence, a specimen that cannot be matched to its patient, a product measurement that fails a release criterion, a count that fails to recover on schedule, or a chimerism or MRD trend that moves the wrong direction, is a signal the laboratory reads and, where policy requires, escalates. The laboratory does not manage the transplant; it produces and interprets the evidence the transplant team needs at each step.